

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137410 A1

(51) International Patent Classification:
C07K 16/24 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/061214

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
20 December 2024 (20.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/612,900 20 December 2023 (20.12.2023) US

(71) Applicant: APOGEE THERAPEUTICS, INC. [US/US];
221 Crescent Street, Waltham, MA 02453 (US).

(72) Inventors: SHAHEEN, Hussam, H.; 221 Crescent Street,
Building 17, Suite 102B, Waltham, MA 02453 (US). THOMPSON, Kenneth, Evan; 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (US). HARWIN, Peter; 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (US). KISELAK, Tomas; 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (US). DABORA, Rebecca, Lucille; 221 Crescent Street, Waltham, MA 02453 (US). PRENTICE, Holly; 221 Crescent Street, Waltham, MA 02453 (US).

(74) Agent: REMILLARD, Jane, E. et al.; Nelson Mullins Riley & Scarborough LLP, One Financial Center, Suite 3500, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF ANTI-IL-13 ANTIBODIES WITH AND WITHOUT C-TERMINAL LYSINE

(57) Abstract: Described herein are pharmaceutical compositions of anti-interleukin (IL)-13 antibodies comprising a mixture of anti-bodies with and without C-terminal lysine extension. Also provided are pharmaceutical compositions for use in the treatment of an inflammatory disease or disorder.

WO 2025/137410 A1